Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 millionPUBT·Jul 16 at 08:04 AMINBX-3.36%
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & Morerttnews·Jun 24 at 09:09 AMINBX-3.36%PVLA+0.75%
Inhibrx Biosciences's BLA Filing For Ozekibart Gets FDA Acceptancerttnews·Jun 15 at 08:35 AMINBX-3.36%
Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)Tip Ranks·May 15 at 07:45 AMINBX-3.36%PBE+2.10%
Inhibrx Reports First Quarter 2026 Financial Results | INBX Stock NewsStockTitan·May 14 at 07:02 AMINBX-3.36%PBE+2.10%
Inhibrx announces positive interim results from HexAgon trialWorldPharmaceuticals·May 12 at 03:42 AMINBX-3.36%BIB+1.90%
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer StudyMarket Beat·May 11 at 11:08 AMINBX-3.36%MRK+0.81%
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | INBX Stock NewsStockTitan·May 10 at 11:00 PMINBX-3.36%BBH+2.95%
